This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nicole Urken

Research Director of Mad Money

Nicole Urken is Research Director of Mad Money and Jim Cramer's researcher at TheStreet. Nicole analyzes stocks and develops a strategic macro outlook, which she incorporates into segment ideas for CNBC's "Mad Money." Nicole also supports Jim's other endeavors including "Squawk on the Street," RealMoney.com, and his latest best-selling book "Get Rich Carefully."

Previously, she worked as an investment banking analyst for the Industrials Group in Goldman Sachs' New York office. Born and raised in Princeton, New Jersey, Nicole graduated with honors from Harvard College, where she served as executive editor of The Harvard Crimson.

Nicole Urken
By This Author:
Page 2 of 15

Two Acquisition Winners: Post Holdings and Zebra Technologies

By Nicole Urken

The bottom line? We haven't seen a huge amount of M&A this year, but it always key to recognize the winners when they come....

02:15PM 05/06/14

The IPO Risk-Factor in the Market

By Nicole Urken

As a follow-up to my previous post, am including a more in-depth analysis of the aftermarket performance of IPOs. As has been noted, plaguing the markets year to date has been the bloodbath in the momentum names--particularly names with no earnings. One thesis regarding the pain in these names is the simple law of supply and demand. Simply put, there is just too much supply....Just look at these aftermarket returns...

01:23PM 05/06/14

Botox at the Center of Recent Healthcare M&A Flurry

By Nicole Urken

How wrinkle reduction is at the crux of the recent M&A frenzy....

11:07AM 04/24/14

Is the robust IPO market affecting the broader indices?

By Nicole Urken

There has been a lot of debate of late about whether some of the pain in the so-called momentum names in the last month has something to do with growth money coming into the IPO space...

03:53PM 04/10/14

The Momentum Tell and the Yellen Timeline

By Nicole Urken

Talk about whiplash. Yesterday's surge upward was met today with, well, a selloff. So, what gives? What's happening here.

02:47PM 04/10/14

Under Armour is cheap! (yes, I said cheap)

By Nicole Urken

This junior growth name still has much room to run based on market potential and new roll-outs.

06:26PM 03/27/14

FedEx Corp is a Buy

By Nicole Urken

Even after a lackluster quarter, future remains bright for FedEx

01:58PM 03/19/14

Tech in Transition: The Winners

By Nicole Urken

Transitions, if believed, allow investors to look through short term disruption

11:01AM 03/19/14

Spin = Win

By Nicole Urken

The news that Hertz is spinning off its equipment rental business reinforces why it remains the best positioned in the car rental group

07:41PM 03/18/14

The Lesson of Allergan

By Nicole Urken

Just over one year ago, when Allergan stood at about $115, worries abounded, causing the stock to drop to the low $80s by the middle of 2013, as the overall equity market continued to roar. This underperformance spooked many investors, but that low was a huge opportunity, as the stock has posted a stellar run ever since, now at new highs at over $130. I bring this up now because many are talking about a bubble in biotech, particularly given surges from recent IPOs.

07:17PM 03/18/14

Page 2 of 15

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,976.94 -5.65 -0.03%
S&P 500 1,976.05 -2.86 -0.14%
NASDAQ 4,448.7050 +3.7960 0.09%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs